Plain-English translation of NCT04891237 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new allergy treatment given as subcutaneous immunotherapy (shots under the skin) to help people who are allergic to grass and olive pollen. Participants will receive either the active medication, a different dose of the active medication, or a placebo (inactive shot) over the course of one year. The goal is to see if this treatment can reduce allergy symptoms and improve quality of life.
Many people suffer from allergies to grass and olive pollen that cause sneezing, congestion, and other bothersome symptoms. This medication aims to train the immune system to be less reactive to these pollens, offering a longer-term solution than just treating symptoms with antihistamines or steroid sprays.
You likely qualify if…
You likely don't qualify if…
You will receive weekly or regular injections of either the active treatment or placebo under your skin for up to one year. Throughout the study, you will use your smartphone to record your allergy symptoms and any medications you take each day. You will visit the clinic multiple times to receive injections and have your response to the treatment monitored.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Spain